|Articles|September 13, 2007

Lancaster Laboratories Acquires Microchem Laboratories in Ireland

Author(s)BioPharm International Editors

Lancaster Laboratories Inc., (Lancaster, PA, www.lancasterlabs.com), part of Thermo Fisher Scientific Inc., (Walthan, MA), has acquired Microchem Laboratories, located in County Waterford, Ireland.

Lancaster Laboratories Inc., (Lancaster, PA, www.lancasterlabs.com), part of Thermo Fisher Scientific Inc., (Walthan, MA), has acquired Microchem Laboratories, located in County Waterford, Ireland. Established in 1986, Microchem is one of Ireland's leading testing and research laboratories, employing over 100 people at its facility. The laboratory offers microbiological, chemical and environmental analyses to the pharmaceutical, medical device, food and chemical industries in Europe and Asia. Microchem will operate as a division of Lancaster Laboratories.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 2nd, 2026

The BioPharm Brief: Room Temperature, RNA, and ADCs

CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.

October 2nd, 2026

Amino Acid Count Determines Retatrutide's Biologic or Drug Classification

LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.

Close-up of an older person's hands, with the thumb of one hand pressing into the palm of the other, against a blurred teal background. | Image Credit: © eyepark - stock.adobe.com

October 2nd, 2026

Artiva to Present AlloNK Data Showing CAR T-Like B-Cell Depletion in Rheumatologic Diseases at ACR 2026

Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.

3D illustration of three golden spherical nanoparticles, one shown in cross-section to reveal a layered lipid shell, with a blue helical nucleic acid strand winding around them against a black background. | Image Credit: © Love Employee - stock.adobe.com

October 2nd, 2026

Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases

Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.

Tablet, science team and people learning for cancer cure, help or medical development in laboratory. Training, investigation or research info with scientists in clinical trial for medicine internship | Image credit: © CoetzeeRising/peopleimages.com - © CoetzeeRising/peopleimages.com - stock.adobe.com

October 2nd, 2026

CaseBioscience Joins $7.3 Million ARPA-H Team on Cell Preservation

The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.

antibody-drug conjugation modality impacts overall therapeutic efficacy in brain tumors 3d rendering | Image credit: © Love Employee - © Love Employee - stock.adobe.com

October 2nd, 2026

AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab

A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.

October 1st, 2026

Former FDA Oncology Reviewer Paz Vellanki on Novel Endpoints and Early FDA Engagement Under CDER's ARC Program

Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.

3D illustration of a single-stranded RNA molecule with nucleotide bases extending from a twisting backbone, shown in purple, pink, and yellow against a black background. | Image Credit: © Dr_Microbe - stock.adobe.com

October 1st, 2026

Wave Life Sciences Aligns With FDA on Registrational Path for RNA Editing Therapy WVE-006 in AATD

Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.